Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.
作者： Lillian R. Klug , Jason D. Kent , Michael C. Heinrich
DOI: 10.1016/J.PHARMTHERA.2018.06.016
关键词:
摘要: … for patients with activation loop mutations in KIT, PDGFRA, or FLT3. … This article reviews the inactive and active structures of KIT, … EGFR mutations seen in lung cancer promote the active …
elsevier.com
sci-hub.se 参考文章(107)
S. Lev, D. Givol, Y. Yarden, A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. The EMBO Journal. ,vol. 10, pp. 647- 654 ,(1991) , 10.1002/J.1460-2075.1991.TB07993.X
Iwona Wlodarska, Anna Aventı́n, Júlia Inglés-Esteve, Daniela Falzetti, Arnold Criel, Jean-Jacques Cassiman, Cristina Mecucci, Herman Van den Berghe, Peter Marynen, A New Subtype of Pre-B Acute Lymphoblastic Leukemia With t(5; 12)(q31q33; p12), Molecularly and Cytogenetically Distinct From t(5; 12) in Chronic Myelomonocytic Leukemia Blood. ,vol. 89, pp. 1716- 1722 ,(1997) , 10.1182/BLOOD.V89.5.1716
M. Schwab, Encyclopedia of Cancer Springer. ,(2009)
SD Lyman, L James, L Johnson, K Brasel, P de Vries, SS Escobar, H Downey, RR Splett, MP Beckmann, HJ McKenna, Cloning of the human homologue of the murine flt3 ligand : a growth factor for early hematopoietic progenitor cells Blood. ,vol. 83, pp. 2795- 2801 ,(1994) , 10.1182/BLOOD.V83.10.2795.2795
K. Nocka, J. Buck, E. Levi, P. Besmer, Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. The EMBO Journal. ,vol. 9, pp. 3287- 3294 ,(1990) , 10.1002/J.1460-2075.1990.TB07528.X
Peng Wu, Thomas E. Nielsen, Mads H. Clausen, Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discovery Today. ,vol. 21, pp. 5- 10 ,(2016) , 10.1016/J.DRUDIS.2015.07.008
S.A. Forbes, G. Bhamra, S. Bamford, E. Dawson, C. Kok, J. Clements, A. Menzies, J.W. Teague, P.A. Futreal, M.R. Stratton, The Catalogue of Somatic Mutations in Cancer (COSMIC). Current protocols in human genetics. ,vol. 57, ,(2008) , 10.1002/0471142905.HG1011S57
Nick J. Dibb, Stephen M. Dilworth, Clifford D. Mol, Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature Reviews Cancer. ,vol. 4, pp. 718- 727 ,(2004) , 10.1038/NRC1434
C C Smith, K Lin, A Stecula, A Sali, N P Shah, FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors Leukemia. ,vol. 29, pp. 2390- 2392 ,(2015) , 10.1038/LEU.2015.165
Yesid Alvarado, Hagop M. Kantarjian, Rajyalakshmi Luthra, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Zeev Estrov, Michael Andreeff, Jorge E. Cortes, Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations Cancer. ,vol. 120, pp. 2142- 2149 ,(2014) , 10.1002/CNCR.28705